ADC Therapeutics Reports Q2 2025 Financial Results: Earnings Breakdown and Strategic Maneuvers

ADC Therapeutics reported Q2 2025 financial results, with net product revenues of $18.1 million, a net loss of $56.6 million, and a successful $100 million private placement to extend its cash runway. The LOTIS-7 trial demonstrated high efficacy rates, and the company is on track with its LOTIS-5 Phase 3 trial. ADC Therapeutics is undergoing strategic restructuring to focus on its core product, ZYNLONTA, and advancing its PSMA-targeting ADC for prostate cancer. The company aims to expand ZYNLONTA into earlier lines of therapy and explore new therapeutic opportunities.

ADC Therapeutics SA (NYSE: ADCT), a leading global player in antibody drug conjugates (ADCs), has reported its second-quarter 2025 financial results. The company's net product revenues for the quarter reached $18.1 million, while the net loss for the period stood at $56.6 million. However, the company managed to extend its cash runway significantly by completing a $100 million private placement [1].

The quarter's operational highlights include impressive efficacy data from the LOTIS-7 trial, which demonstrated an overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company expects to present additional key clinical milestones in the second half of 2025 [1].

ADC Therapeutics is also on track with its LOTIS-5 Phase 3 trial, which is expected to reach prespecified progression-free survival (PFS) events by the end of 2025. The company has announced a strategic restructuring plan, discontinuing early development efforts for solid tumors and focusing on its core product, ZYNLONTA, and advancing its PSMA-targeting ADC for prostate cancer [1].

The company's financial results for the second quarter and the first half of 2025 show an increase in research and development (R&D) expenses due to the timing and enrollment of its clinical trials and an increase in IND-enabling activities for its PSMA-targeting ADC. Selling and marketing (S&M) expenses decreased due to a reduction in marketing and advertising expenses, while general and administrative (G&A) expenses also decreased due to lower external professional fees. The company incurred restructuring and impairment costs of $13.1 million for the three and six months ended June 30, 2025 [1].

ADC Therapeutics' adjusted net loss for the quarter ended June 30, 2025, was $28.7 million, or $0.25 per basic and diluted share, compared to $24.4 million, or $0.25 per basic and diluted share, for the same period in 2024. The company's cash and cash equivalents as of June 30, 2025, stood at $264.6 million, compared to $250.9 million as of December 31, 2024. The $100 million private placement extended the company's expected cash runway into 2028 [1].

The company's management will host a conference call and live audio webcast to discuss the second quarter 2025 financial results and provide a company update today at 8:30 a.m. Eastern Time [1].

References:
[1] https://www.biospace.com/press-releases/adc-therapeutics-reports-second-quarter-2025-financial-results-and-provides-operational-update